Few nutrients have attracted as much research attention, or generated as much conflicting interpretation, as vitamin D. With thousands of studies published in the last decade, the challenge is no longer finding evidence but knowing which evidence to trust. This same framework for evaluating research quality is central to how Kynorvia approaches peptide science and peptide therapy education.
Vitamin D is not a vitamin
Despite its name, vitamin D functions as a steroid hormone, not a traditional vitamin. It is synthesized in the skin upon exposure to UVB radiation, converted to its active form (1,25-dihydroxyvitamin D, or calcitriol) through sequential hydroxylation steps in the liver and kidneys, and then acts on nuclear receptors found in virtually every tissue in the body, including immune cells.
This receptor distribution is why vitamin D's effects extend far beyond bone metabolism. Vitamin D receptors (VDRs) are expressed on T cells, B cells, natural killer cells, macrophages, and dendritic cells. The presence of these receptors is not coincidental, it reflects a genuine regulatory role in both innate and adaptive immune responses.
What deficiency looks like immunologically
Vitamin D deficiency, defined as serum 25-hydroxyvitamin D below 20 ng/mL, is associated with impaired innate immune responses, reduced production of antimicrobial peptides (particularly cathelicidin and defensins), and dysregulation of inflammatory cytokine production. These are not theoretical associations; they are mechanistically supported by in vitro and in vivo research.
Epidemiological data consistently show higher rates of respiratory infections in populations with lower vitamin D status, and seasonal patterns of respiratory illness correlate with seasonal nadirs in vitamin D levels. However, correlation is not causation, and this is where the literature becomes more nuanced.
Randomized trial evidence: what it actually shows
The most rigorous evidence comes from randomized controlled trials and their meta-analyses. A 2017 individual participant data meta-analysis published in the BMJ (Martineau et al.) analyzed 25 RCTs and found that vitamin D supplementation reduced the risk of acute respiratory tract infection overall, with the strongest protective effect in individuals who were deficient at baseline and who received daily or weekly (rather than bolus) dosing.
The VITAL trial (2019), one of the largest vitamin D RCTs conducted, found no significant reduction in cancer incidence or cardiovascular events with 2,000 IU/day of vitamin D3 in a generally replete population. This is an important finding: supplementation in individuals who are already sufficient appears to provide less benefit than correcting deficiency. The intervention context matters enormously.
D3 vs D2: the form question
Vitamin D3 (cholecalciferol) is the form produced in human skin and found in animal-derived foods. Vitamin D2 (ergocalciferol) is derived from plant sources and fungi. Both are converted to the same active metabolite, but D3 is substantially more effective at raising and sustaining serum 25-hydroxyvitamin D levels.
A meta-analysis comparing the two forms found D3 to be approximately 87% more potent at raising serum 25(OH)D. For immune-related supplementation, D3 is the clinically preferred form. Vegan D3 derived from lichen is now widely available and provides the same efficacy as animal-derived D3 for those avoiding animal products.
Cofactors: vitamin K2 and magnesium
Vitamin D does not act in isolation. Magnesium is required for the enzymatic conversion of vitamin D to its active form, individuals with magnesium deficiency may have impaired vitamin D activation regardless of their supplementation dose. This is one reason why correcting magnesium status is often a prerequisite for effective vitamin D repletion.
Vitamin K2 (menaquinone) is increasingly discussed alongside vitamin D due to its role in directing calcium to bone and away from soft tissues. While the evidence for K2 co-supplementation is not as robust as for vitamin D itself, the theoretical rationale is sound and the safety profile of K2 is favorable. Many clinicians recommend co-supplementation, particularly at higher vitamin D doses.
Practical considerations and upper limits
The tolerable upper intake level (UL) for vitamin D in adults is set at 4,000 IU/day by most regulatory bodies, though many clinical researchers consider this conservative. Toxicity (hypercalcemia) from supplementation is rare and typically requires sustained intake well above 10,000 IU/day. However, individual variation in response is significant, serum testing before and during supplementation is the most reliable way to optimize dosing.
Target serum 25-hydroxyvitamin D levels for immune optimization are generally cited in the range of 40–60 ng/mL, though optimal levels remain debated. Always work with a qualified healthcare provider to establish your baseline, determine an appropriate dose, and monitor levels over time. The information presented here is educational and does not constitute medical advice.
Related peptide education